Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Our mission is to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Dr. Harald HHW Schmidt
Many cardiovascular diseases (CVD) are associated with inflammation, and inflammatory diseases such as rheumatoid arthritis are associated with cardiovascular risk. Different cells appear to be involved, including macrophages and platelets. Yet, no therapies have emerged so far, with the exception of the possible pleiotropic anti-inflammatory effect of statins. Inflammation and response to statin treatment can now be localised and monitored by PET imaging based either on enhanced glucose uptake into metabolically active macrophages in high-risk plaques, or the new agent 11C-PK11195. For example, FDG-glucose uptake into the carotid is the only predictor of recurrent events after stroke and, in the aorta, allows tracking of inflammation during statin therapy. Plaque heterogeneity includes initial glucose signals that later disappear due to increasing calcification.With respect to treatment, ongoing trials are assessing potential new anti-inflammatory approaches using drugs such as mycophenolate, low dose methotrexate (CIRT), the IL-1 inhibitor canakinumab (CANTOS), as well as different inhibitors of IL-6, TNF-alpha, 5-lipoxygenase, FLAP, CCR2, Nox1 and PLA2. Targets from possibly defective anti-inflammatory pathways have apparently not yet been considered. The timing and duration of such interventions, their efficacy, and potential problems such as increased risk of infection need to be studied.
Red hot - new insights on inflammation and cardiovascular disease
© 2017 European Society of Cardiology. All rights reserved